Sterol biosynthesis in Pneumocystis: unique steps that define unique targets

Area of Science:

• Mycology
• Medicinal Chemistry
• Biochemistry

Background:

• Pneumocystis pneumonia (PCP) treatment is challenging because Pneumocystis lacks ergosterol, a common target for antifungal drugs.
• Standard antifungals targeting ergosterol synthesis or binding are ineffective against Pneumocystis.
• Pneumocystis synthesizes unique sterols, including C28 and C29 Delta(7) 24-alkylsterols and Delta(5) 24-alkylsterols.

Purpose of the Study:

• To identify novel targets for antifungal drug development against Pneumocystis pneumonia.
• To investigate the unique sterol biosynthesis pathways in Pneumocystis, specifically C-24 alkylation.
• To characterize the properties of the P. carinii sterol C-24 methyl transferase (SAM:SMT).

Main Methods:

• Analysis of Pneumocystis sterol composition.
• Biochemical characterization of the S-adenosyl-L-methionine:sterol C-24 methyl transferase (SAM:SMT) enzyme from P. carinii.
• Comparison of sterol biosynthesis pathways in Pneumocystis and mammals.

Main Results:

• Pneumocystis synthesizes unique sterols, including 24-alkylated sterols, which differ from mammalian sterols.
• The C-24 alkylation pathway, but not C-22 desaturation, is a viable target for antifungal drug development in P. carinii.
• The P. carinii SAM:SMT enzyme exhibits unique substrate preferences, favoring lanosterol.

Conclusions:

• The unique sterol biosynthesis of Pneumocystis, particularly C-24 alkylation, offers potential targets for new antifungal therapies.
• The P. carinii SAM:SMT enzyme's distinct properties make it an attractive candidate for selective drug inhibition.
• Targeting sterol C-24 alkylation could lead to effective treatments for Pneumocystis pneumonia, overcoming resistance to existing antifungals.